Stay updated with breaking news from பெட்ரா காஃப்மந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Affinia Therapeutics Closes $110 Million Series B Financing Affinia TherapeuticsMay 3, 2021 GMT Financing co-led by EcoR1 Capital and Farallon Capital Management Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management. Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Vent ....
Published: Feb 19, 2021 By Alex Keown PICI – Bristol Myers Squibb veteran Ute Dugan was named Senior Vice President of Clinical Research at the Parker Institute for Cancer Immunotherapy (PICI). She will oversee PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and advancing novel breakthrough treatment combinations. At BMS, she was head of Worldwide Oncology External Medical Affairs, where she created research collaboration models to advance immune-oncology treatments together with partners in academia, professional societies and non-profit organizations. Dugan originally joined BMS as executive director of Global Clinical Research during the formation of the development teams for the pioneering I-O medicines ipilimumab and nivolumab. Before that, her career included stints at Roche/Genentech and Aventis. ....
Samir Mody as chief commercial officer, while Friedrich Asmus signs on as SVP, clinical development and medical affairs. Meanwhile, the company has also tapped Joel Centeno as SVP, manufacturing, quality and supply chain. Mody comes over from Medtronic, where he was vice president, CRHF strategy, health economics and reimbursement. Asmus previously served as VP of clinical development at ophthalmology biotech ProQR Therapeutics, while Centeno comes over after stints at Boston Scientific, Hologic and AltheaDx. Tamra Adams as chief financial officer, a newly created executive position at the company. Before joining Antios, Adams founded Accounting Concepts, which provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics. ....
Home / Top News / Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer Gene therapy development expert Petra Kaufmann, M.D., joins as chief medical officer – WALTHAM, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced the completion of its leadership team. Collectively, the executives represent a diverse team of proven leaders in gene therapy who have successfully developed novel platforms ....
This feature article was originally published in Outdoor Canada magazine’s 2002 Hunting Special. We republished the piece in our May/June 2020 issue in memory of the award-winning author, Jake MacDonald (below), who died following an accidental fall on January 30, 2020, in Puerto Vallarta, Mexico. Seventy years young, Jake was one of our long-time writers, and his voice and innumerable contributions will be sorely missed. This particular story is emblematic of his wonderful writing style, which was at once insightful, charming, thought-provoking and witty. Jake had a deep love and connection with the outdoors and the people who shared his affinity for fishing and hunting, and it shows through in this piece. Not surprisingly, the story earned Jake the top award from the Outdoor Writers of Canada for magazine feature writing about hunting. The article also garnered him an honourable mention from the National Magazine Awards. Our deepest condolences go out to Jake’s family, ....